Physician profile
Howard Dedes
NPI 1679760094
$16,821.52
in general payments reported to CMS, 2019-2025
40 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what 79% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $614 · 2021: $1,012 · 2022: $3,112 · 2023: $5,764 · 2024: $3,322 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,357 · Travel and Lodging: $3,752 · Education: $57.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,356.89 |
| Travel and Lodging | $3,751.94 |
| Education | $57.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,752.77 | 2019-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, Infinion 16 |
| Saluda Medical Americas, INC. | $2,733.97 | 2023-2025 | Evoke Scs, Evoke |
| Medtronic, INC. | $1,854.96 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Abbott Laboratories | $1,588.66 | 2019-2024 | Eterna, Proclaim |
| Curonix LLC | $1,520.30 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Relievant Medsystems, INC. | $1,335.96 | 2022-2023 | Intracept |
| Abbvie INC. | $932.93 | 2022-2025 | Qulipta, Botox, Ubrelvy |
| Si-Bone, INC. | $457.90 | 2020-2025 | |
| Nevro Corp. | $401.42 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $355.99 | 2022-2025 | Belbuca |
| Vertos Medical, INC. | $329.06 | 2021-2024 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $261.91 | 2022 | |
| Pfizer INC. | $223.75 | 2023-2025 | |
| Stimwave Technologies Incorporated | $214.86 | 2019-2022 | |
| Allergan, INC. | $195.56 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $148.88 | 2021-2024 | Sprint Pns System |
| Forte Bio-Pharma LLC | $144.55 | 2019-2022 | |
| Bioventus LLC | $139.20 | 2024 | Stimrouter Implantable Kit |
| Medtronic USA, INC. | $118.69 | 2019 | |
| Stryker Corporation | $116.51 | 2021-2024 | Mild Device Kit |
| Biotronik Nro, INC. | $99.25 | 2024-2025 | Prospera |
| Painteq LLC | $84.78 | 2022-2023 | Painteq |
| Nalu Medical, INC. | $83.92 | 2023-2024 | Nalu Neurostimulation System |
| Biohaven Pharmaceuticals, INC. | $83.59 | 2021 | |
| Amgen INC. | $78.20 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $63.94 | 2019-2021 | |
| Lilly USA, LLC | $56.65 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $56.03 | 2023-2024 | Ztlido |
| Grt US Holding, INC. | $55.31 | 2021-2022 | |
| Djo, LLC | $44.61 | 2024 | Procare |
| Valinor Pharma, LLC | $39.34 | 2023 | Movantik |
| Impel Pharmaceuticals INC. | $38.80 | 2023 | Trudhesa |
| Merz Pharmaceuticals, LLC | $37.40 | 2024 | Xeomin |
| Kowa Pharmaceuticals America, INC. | $36.91 | 2023 | Seglentis |
| Averitas Pharma INC. | $35.00 | 2024 | Qutenza |
| Spinal Simplicity, LLC | $29.58 | 2024 | Ha Minuteman G3-R |
| Tersera Therapeutics LLC | $22.91 | 2023 | Prialt |
| Globus Medical, INC. | $22.84 | 2025 | Senza |
| Redhill Biopharma INC. | $13.22 | 2020 | |
| Neuronetics, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Dedes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.